Jinfeng Pill

Phase 3Small molecule

PPeking Union Medical College Hospital

Jinfeng Pill is one of 52 small molecule programs targeting Polycystic Ovary Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polycystic Ovary SyndromeActive, not recruiting

Polycystic Ovary SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

71 competitors in Polycystic Ovary Syndrome

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Approved

56 2

Femara

Novartis

Approved

10 3

Avandia

Jazz Pharmaceuticals

Approved

2 4

Myrbetriq

Astellas

Approved

1 5

Daliresp

AstraZeneca

Approved

1 6

Onglyza

Evista

Calciferol

Alli

EEngelhard Arzneimittel GmbH & Co.KG

Approved

3 10

Glucophage

EMD Serono

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Polycystic Ovary Syndrome1 trial

Clinical、metabolomics and the Study of Intestinal Flora of Jinfeng Pills in the Treatment of Polycystic Ovary Syndrome

Active, not recruiting·PPeking Union Medical College Hospital·Phase 4·NCT06823830·105 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Jinfeng Pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Jinfeng Pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Jinfeng Pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking Union Medical College Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPeking Union Medical College Hospital

Jinfeng Pill

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Polycystic Ovary Syndrome1 trial

References

Drug Info

Quick Facts

Related News